🤖 Anthropic Is Making Its Own Drugs — And That's Just the Start

AI just got a lot more complicated. Anthropic is pivoting hard into pharmaceutical development while simultaneously negotiating a custom chip deal with Samsung — signaling a new era of vertical integration that goes far beyond chatbots. OpenAI's Sam Altman is reportedly pushing to hand five percent of the company's equity to a US sovereign wealth fund, raising urgent questions about who really benefits from the AI wealth explosion. In the UK, authorities are sounding the alarm for parents everywhere, warning that AI-powered 'nudification' apps are being used to exploit children's publicly posted photos in deeply disturbing ways. The question of whether human or AI-generated writing can even be told apart is no longer theoretical — it's now landing in courtrooms, newsrooms, and literary circles. Meanwhile, at Google DeepMind, employees trying to unionize are hitting walls, and a broader philosophical debate is gaining traction: has AI's ethical direction already been quietly decided by financial incentives, long before the rest of us got a vote?Subscribe to Daily Inference: dailyinference.comLove AI? Check out our other AI tools: 60sec.site and Artificial Intelligence Radio